AXSOME THERAPEUTICS INC

Axsome insider Jeffs sells 286 shares for $246.18—routine tax‑plan activity that won’t sway stock price or alter control, but shows steady executive alignment.

Insider buying at Axsome Therapeutics signals confidence in its CNS pipeline. Discover how exec trades, market momentum, and digital health adoption could shape future value.

Axsome Therapeutics’ insider buying signals leadership confidence, highlighting strategic alignment, market‑access tactics, and a solid drug‑development roadmap that investors should watch.

Axsome insider sale: senior director Coleman Mark sells 6 000 shares at ~$233, a disciplined 10b‑5 plan that signals confidence, not a bearish signal, amid strong pipeline growth.

Axsome COO’s routine 10b5‑1 trades show balanced buying/selling at peak prices, reflecting confidence in the company’s growth and a neutral short‑term outlook.

Axsome’s insider purchases signal confidence in Auvelity’s FDA fate and pipeline growth, showing how executive PSUs align with commercial milestones and investor upside.

Axsome Therapeutics COO’s fresh RSU purchase signals insider confidence—potentially easing short‑term pressure as the CLARITY trial advances and the company expands its CNS portfolio.

Insider buying signals optimism for Axsome Therapeutics: executive Coleman Mark’s recent 6,250‑share purchase at $4.95 underscores confidence in the company’s commercial momentum and Phase 3 pipeline, hinting at upside potential amid a negative P/E …

Axsome insider buys 12,485 shares—signaling confidence despite a $183.72 dip. Explore what this means for investors and the company’s regulatory outlook.

Axsome CFO’s 12,000‑share buy‑sell cycle shows confident insider bets on the drug pipeline, with strategic 10(b)(5)(1) trades that signal long‑term optimism and clear liquidity management.